Cumberland Pharma

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its product include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, and RediTrex. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cumberland Pharma reports steady Q1 performance amidst sales challenges

Cumberland Pharma's Q1 2024 performance showcased resilience in the face of sales challenges, with a strategic emphasis on FDA-approved brands. The company's dedication to innovation and patient care underpins its growth trajectory, despite hurdles posed by insurance deductibles.

Cumberland Pharma reports revenue growth but faces profitability challenges

Cumberland Pharmaceuticals demonstrated revenue growth potential but grappled with profitability challenges in Q2 2024. The company's focus on innovation, market expansion, and patient care underscores a commitment to long-term success. Addressing cost management, profitability, and leveraging growth opportunities will be crucial for Cumberland's future.

Cumberland Pharma reports resilient Q3 performance amidst operational challenges

Cumberland Pharma's Q3 2024 performance was driven by FDA-approved brands despite challenges.
The company showcased improved financials with a focus on operational efficiency and growth opportunities.
While facing challenges like product returns and expenses, Cumberland maintains a strong financial position.
Strategic initiatives and research efforts position Cumberland for future growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. Its products include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, Sancuso, Boxaban, Vasculan. Dyscorban, and RediTrex. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.

CUMBERLAND PHARMACEUTICALS ACQUIRES SANCUSO® FROM KYOWA KIRIN NORTH AMERICA

Banco Bradesco

BIOLASE

Check these three penny stocks out for your watchlist right now The post Top Trending Penny Stocks to Buy Now? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Trending Penny Stocks to Buy Now? 3 to Watch

Allied Esports Entertainment Inc

Harbor Custom Development, Inc.

Spark Networks

Outlook Therapeutics Inc

PEDEVCO

Party City Holdco

Selecta Biosciences

Vyne Therapeutics

Corporate insiders buy penny stocks & these 10 are getting purchased in December 2021. The post 10 Penny Stocks To Buy In December According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Penny Stocks To Buy In December According To Insiders

The stock price of Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) increased by 51.2% today. This is why it happened.

Cumberland Pharmaceuticals Stock (CPIX): Why The Price Surged Today

Yes, even insiders buy penny stocks & here are 5 getting scooped up in December 2021. The post 5 Penny Stocks To Buy In December According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Buy In December According To Insiders

Cidara Therapeutics

CTI BioPharma

Penny stocks to watch even with Biotech ETFs heading lower today. The post 3 Biotech Penny Stocks To Watch With The Stock Market Down Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Biotech Penny Stocks To Watch With The Stock Market Down Today

Ardelyx

Nautilus Biotechnology

Petros Pharmaceuticals

Are these on your list of penny stocks to buy this week? The post Penny Stocks To Buy This Week: 4 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy This Week: 4 To Watch Right Now

Harmony Gold Mining Co Ltd

ImmunoGen

Here's three penny stocks to watch with the market down today The post List of Penny Stocks to Watch While The Stock Market is Down Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

List of Penny Stocks to Watch While The Stock Market is Down Today

Cumberland Pharmaceuticals stock is up more than 90% in morning trading after the FDA approved the expanded use of its pain medication. The post CPIX Stock Alert: Cumberland Pharma Doubles on FDA Approval News appeared first on InvestorPlace.

CPIX Stock Alert: Cumberland Pharma Doubles on FDA Approval News

The FDA has approved expanded labeling for Cumberland Pharmaceuticals Inc's (NASDAQ: CPIX) Caldolor, an intravenously delivered formulation of ibuprofen, to now include use in pre-operative administration.  The non-narcotic pain reliever can now be administered just before surgery to enable patients to wake up from their procedure in significantly less pain.

Read Why Shares Of Nano Cap Cumberland Pharma More Than Doubled

The stock price of Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) increased by over 115% pre-market today. This is why it happened.

Cumberland Pharmaceuticals (CPIX) Stock: Why The Price Surged Today

NASHVILLE, Tenn., Nov. 29, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has approved expanded labeling for Caldolor®, an intravenously delivered formulation of ibuprofen, to now include use in pre-operative administration.

Caldolor® Now FDA Approved For Pre-Operative Administration

Cumberland Pharmaceuticals Inc. (CPIX) CEO A.J. Kazimi on Q3 2021 Results - Earnings Call Transcript

NASHVILLE, Tenn., Nov. 9, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and third quarter 2021 financial results.

Cumberland Pharmaceuticals Reports Third Quarter 2021 Financial Results & Company Update

NASHVILLE, Tenn., Nov. 2, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2021 financial results and provide a Company update after the market closes on Tuesday, November 9, 2021.

Cumberland Pharmaceuticals To Announce Third Quarter 2021 Financial Results

NASHVILLE, Tenn., Sept. 29, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today the national launch of its RediTrex ® (methotrexate) line of pre-filled syringes designed for the safe and simple treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis.

Cumberland Pharmaceuticals Launches RediTrex® Product Line For Active Rheumatoid, Juvenile Idiopathic And Severe Psoriatic Arthritis

Cumberland Pharmaceuticals, Inc. (CPIX) CEO A.J. Kazimi on Q2 2021 Results - Earnings Call Transcript

Cumberland (CPIX) delivered earnings and revenue surprises of 100.00% and 5.66%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Cumberland Pharmaceuticals (CPIX) Reports Break-Even Earnings for Q2

NASHVILLE, Tenn., Aug. 10, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and second quarter 2021 financial results.

Cumberland Pharmaceuticals Reports Second Quarter 2021 Financial Results & Company Update

Cumberland (NASDAQ:CPIX) announces its next round of earnings this Tuesday, August 10. Here is Benzinga's everything-that-matters guide for this Tuesday's Q2 earnings announcement.

Earnings Preview: Cumberland

Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Cumberland Pharmaceuticals (CPIX) Q2 Earnings Expected to Decline

NASHVILLE, Tenn., Aug. 3, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release second quarter 2021 financial results and provide a Company update after the market closes on Tuesday, August 10, 2021.

Cumberland Pharmaceuticals To Announce Second Quarter 2021 Financial Results

NASHVILLE, Tenn., July 26, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today released its 2020 Sustainability Report, which details the company's activities pertaining to environmental, social and governance (ESG) matters.

Cumberland Pharmaceuticals Reports 2.5M Patient Doses Delivered, No Product Recalls, No FDA Issues in 2020

Mitcham Industries

Madison Square Garden Entertainment

John Rogers (Trades, Portfolio), leader of Ariel Investments, disclosed last week his firm made changes to its portfolio on June 30.

News for Cumberland Pharma Stock (CPIX)